Roche says divarasib cut risk of death 44% in lung cancer trial

Swiss drugmaker Roche said on Sunday its experimental lung cancer drug divarasib reduced ​the risk of death by 44% compared ‌with existing treatments in a phase III study.

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.reuters.com)